# A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants

> **NCT06370728** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Carbamazepine

## Key facts

- **NCT ID:** NCT06370728
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-06
- **Primary completion:** 2024-07-23
- **Final completion:** 2024-07-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06370728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06370728, "A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06370728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*